Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy.

ABSTRACT: Chronic heart failure (CHF) is a major contributor to cardiovascular disease and is the leading cause of hospitalization for those over the age of 65, which is estimated to account for close to seventy billion dollars in healthcare costs by 2030 in the US alone. The successful therapies for preventing and reversing CHF progression are urgently required. One strategy under active investigation is to restore dysregulated myocardial calcium (Ca2+), a hallmark of CHF. It is well established that intracellular Ca2+ concentrations are tightly regulated to control efficient myocardial systolic contraction and diastolic relaxation. Among the many cell surface proteins and intracellular organelles that act as the warp and woof of the regulatory network controlling intracellular Ca2+ signals in card

SUBMITTER: Samuel TJ 

PROVIDER: S-EPMC5979534 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature